[EN] A PHARMACEUTICAL COMPOSITION FOR TREATING ATAXIA, MULTIPLE SYSTEM ATROPHY OR BALANCE DISORDERS [FR] PRÉPARATION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'ATAXIE, DE L'ATROPHIE MULTISYSTÉMIQUE, OU DE TROUBLES DE L'ÉQUILIBRE
[EN] A PHARMACEUTICAL COMPOSITION FOR TREATING ATAXIA, MULTIPLE SYSTEM ATROPHY OR BALANCE DISORDERS [FR] PRÉPARATION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'ATAXIE, DE L'ATROPHIE MULTISYSTÉMIQUE, OU DE TROUBLES DE L'ÉQUILIBRE
Pharmaceutical Composition for Treating Spinocerebellar Ataxia
申请人:Yoshikawa Takayoshi
公开号:US20080027116A1
公开(公告)日:2008-01-31
This invention provide to a pharmaceutical composition for treating spinocerebellar ataxia (or atrophy, degeneration) or multiple system atrophy, or for improving ataxia or equilibrium disturbance comprising a compound of the formula (I):
wherein R is methyl, cyano or carbamoyl, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.
Pharmaceutical composition for treating spinocerebellar ataxia
申请人:Shionogi & Co., Ltd.
公开号:US08071633B2
公开(公告)日:2011-12-06
This invention provide to a pharmaceutical composition for treating spinocerebellar ataxia (or atrophy, degeneration) or multiple system atrophy, or for improving ataxia or equilibrium disturbance comprising a compound of the formula (I):
wherein R is methyl, cyano or carbamoyl, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.
A PHARMACEUTICAL COMPOSITION FOR TREATING ATAXIA, MULTIPLE SYSTEM ATROPHY OR BALANCE DISORDERS
申请人:Shionogi & Co., Ltd.
公开号:EP1786423B1
公开(公告)日:2019-03-13
[EN] A PHARMACEUTICAL COMPOSITION FOR TREATING ATAXIA, MULTIPLE SYSTEM ATROPHY OR BALANCE DISORDERS<br/>[FR] PRÉPARATION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'ATAXIE, DE L'ATROPHIE MULTISYSTÉMIQUE, OU DE TROUBLES DE L'ÉQUILIBRE
申请人:SHIONOGI & CO
公开号:WO2006028277A1
公开(公告)日:2006-03-16
This invention provides a pharmaceutical composition for treating spinocerebellar ataxia (or atrophy, degeneration) or multiple system atrophy, or for improving ataxia or equilibrium disturbance comprising a compound of the formula (I): wherein R is methyl, cyano or carbamoyl, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.